Patents for A61P 35 - Antineoplastic agents (221,099)
02/2004
02/26/2004WO2003057144A3 Change inhibitors of dipeptidyl peptidase iv
02/26/2004WO2003051837A3 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
02/26/2004WO2003045334A3 Methods and compositions for ameliorating the undesirable effects of chemotherapy
02/26/2004WO2003040144A3 Heterocyclic compound based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds
02/26/2004WO2003031381A3 Synthesis of (z)-3,5,4'-trimethoxystilbene, and use thereof
02/26/2004WO2003026568A3 Androstanes as androgen receptor modulators
02/26/2004WO2003020892A3 Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
02/26/2004WO2003016472A9 Hybrid interferon/interferon tau proteins, compositions and methods of use
02/26/2004WO2003013541A8 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
02/26/2004WO2003008449A8 Ntb-a, a surface molecule involved in natural killer cells activity
02/26/2004WO2003006425A9 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
02/26/2004WO2002103014A3 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells
02/26/2004WO2002102973A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
02/26/2004WO2002099047A3 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
02/26/2004WO2002098501A3 Method and apparatus for treating tumors using low strength electric fields
02/26/2004WO2002098424B1 Novel anti-infectives
02/26/2004WO2002094322A3 Combination medicament for treatment of neoplastic diseases containing cyanoguanidine ikk inhibitors and a second anti-neoplastic drug
02/26/2004WO2002092012A9 Compositions and methods for treating tumors bearing hmfg and cea antigens
02/26/2004WO2002083917A8 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
02/26/2004WO2002083067A9 Prodrugs via acylation with cinnamate
02/26/2004WO2002081491A3 New genistein derivatives and pharmaceutical preparations containing them
02/26/2004WO2002072636A8 Crystals of whole antibodies and fragments thereof and methods for making and using them
02/26/2004WO2002069988A3 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation
02/26/2004WO2002055075A9 Compounds and methods for regulating cell differentiation
02/26/2004WO2002055067A3 Fumaric acid derivatives as nf-kappab inhibitors
02/26/2004WO2002046418A3 Lipid-associated molecules
02/26/2004WO2002046382A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
02/26/2004WO2002033089A3 Ixodes scapularis tissue factor pathway inhibitor
02/26/2004WO2002022112A3 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
02/26/2004WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis
02/26/2004WO2001057175A3 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
02/26/2004US20040039298 Noninvasive measurement of chemical substances
02/26/2004US20040039297 Noninvasive measurement of chemical substances
02/26/2004US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides
02/26/2004US20040039196 (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors
02/26/2004US20040039184 Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
02/26/2004US20040039160 Comprises therapeutic agent, oligopeptide having an isoleucine residue, stabilizing group, and, optionally, a linker group; prodrug is cleavable by an enzyme associated with target cell; antitumor agents
02/26/2004US20040039061 Suppress expression and induction of inflammatory cytokines, cell adhesion molecule gene and virus and suppressors for nuclear factor kappa beta (nf-kb)
02/26/2004US20040039038 Biaromatic compound activators of PPARy-type receptors
02/26/2004US20040039029 Thiazolyl urea compounds and methods of uses
02/26/2004US20040039027 Sulfur compounds such as (2-(((3-Methyl-4-(2,2,2-trifluoro-ethoxy)-2-pyridinyl)methyl)sulfinyl)-1H -benzimidazol-1-yl) methyl benzoate, administered as prodrugs for lansoprazole; proton pump inhibitors; gastrointerstinal disorders
02/26/2004US20040039026 Macromolecules such as (12R,13S,15S)-cyclopropyl 5-methyl-pyridine epothilone A, used as tubulin polymerization promoters and for cytolysis cancer cells; antiproliferative agents
02/26/2004US20040039015 Estrogen Receptor-beta ligands
02/26/2004US20040039012 Nitrogen compounds such as Benzyl-8-methyl-5,7-dioxo-1,5,6,7-tetrahydro-(1,2,4)triazolo(1,5-a)pyridine -2-carboxylic acid benzylamide, used for prophylaxis of arthritis, inflammation or cancer
02/26/2004US20040039006 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use
02/26/2004US20040039004 Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders
02/26/2004US20040039002 6,7-Dimethoxyquinazolines and therapeutic use thereof
02/26/2004US20040038995 Inhibitors of both KDR an FGFR kinases and are selective against LCK; for treatment of solid tumors, in particular breast, colon, lung and prostate tumors.
02/26/2004US20040038978 Chemical compounds
02/26/2004US20040038977 Treating arthritis, pain and cancer
02/26/2004US20040038964 Imidazole derivatives as raf kinase inhibitors
02/26/2004US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc.
02/26/2004US20040038949 Inhibitors of the enzyme CYP24; useful for treating cell-proliferative disorders and for promoting cell differentiation.
02/26/2004US20040038943 Indole and benzimidazole 15-lipoxygenase inhibitors
02/26/2004US20040038941 Compounds for the treatment of inflammatory disorders
02/26/2004US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity
02/26/2004US20040038927 Methods of decreasing or preventing pain using spicamycin derivaties
02/26/2004US20040038921 Comprises double-stranded oligoribonucleic acid (dsRNA); hammerhead ribozymes
02/26/2004US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity
02/26/2004US20040038913 Remedies for lung cancer
02/26/2004US20040038905 Anticancer agents
02/26/2004US20040038903 Gonadotropin releasing hormone antagonists in gel-forming concentration
02/26/2004US20040038889 Fumaric acid amides
02/26/2004US20040038886 Chimeric cytoplasmic signalling molecules derived from cd137
02/26/2004US20040038879 For therapy and prophylaxis of infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, cancers, anorexia, bulimia, asthma, Parkinson's disease, acute heart failure
02/26/2004US20040038877 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
02/26/2004US20040038873 Used for the manufacture of medicine for the treatment of developmental disorders, diseases caused by abnormal metabolism of immune system, and cancers
02/26/2004US20040038871 Attaching a linker to an amino group of the drug, the linker including an aldehyde or ketone carbonyl group, and forming an oxime by reaction of the carbonyl group with an O-alkylhydroxylamine derivative of the peptide
02/26/2004US20040038858 Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours
02/26/2004US20040038402 Gene therapy; for production of transgenic animal models
02/26/2004US20040038370 Claudin polypeptides
02/26/2004US20040038363 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
02/26/2004US20040038361 Novel protein kinase (NPK-110)
02/26/2004US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
02/26/2004US20040038324 Epothilone resistant cell lines
02/26/2004US20040038293 Antibodies to human cd154
02/26/2004US20040038284 Using replication error phenotype (RER) to classify and prognose tumor disorders; immunoassay
02/26/2004US20040038278 Methods and compositions relating to gene silencing
02/26/2004US20040038274 Gapped 2' modified oligonucleotides
02/26/2004US20040038271 Novel C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
02/26/2004US20040038265 Using low density lipoprotein related proteins (LRP) to diagnose, treat and prevent paget's, osteoporosis, cirrhosis and rickets
02/26/2004US20040038257 Therapeutic peptidase for diagnosis, treatment and prevention of cancer and nervous system disorders
02/26/2004US20040038243 P53-dependent apoptosis-associated protein and method of screening apoptosis controlling agent
02/26/2004US20040038238 Comprises chimeric membrane proteins for diagnosis, treatment and prevention of inflammation, cancer, metabolic, gastrointestinal and autoimmune disorders
02/26/2004US20040038235 A g-protein coupled receptor
02/26/2004US20040038230 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
02/26/2004US20040038223 Comprise polypeptide for diagnosis, prevention and treatment of cardiomyopathy, atherosclerosis, hypertension, cancer, diabetes and nervous system disorders
02/26/2004US20040038212 Novel armadillo repeat-containing protein alex1
02/26/2004US20040038209 Comprises nucleotide sequences coding beta -carotene dioxygenase which cleaves beta carotene and produces vitamin a aldehyde; improving nutritional value of plants, microorganisms and animal feeds
02/26/2004US20040038205 Modified adenoviral fiber and uses
02/26/2004US20040037843 Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
02/26/2004US20040037833 Comprises purified imunoglobulin polypeptide or antigen binding fragment for diagnosis of disease/cancer
02/26/2004US20040037831 Pharmaceutical compositon comprising trkaig2 for use inthe prevention and/or treatment of cancer
02/26/2004US20040037824 Epidermal growth factors (ErbB2); gene expression inhibition; anticancer agents
02/26/2004US20040037823 Epidermal growth factors (ErbB2); comprises doxorubicin; gene expression inhibition; anticancer agents
02/26/2004US20040037815 Isolation and use of solid tumor stem cells
02/26/2004DE3921022B4 Mitomycinphosphatderivat und pharmazeutisches Mittel, das diese Verbindung als Antitumorwirkstoff enthält Mitomycinphosphatderivat and pharmaceutical agent containing this compound as an antitumor agent
02/26/2004DE10232020A1 Neurorezeptoraktive Heteroarencarboxamide Neuroreceptor Active Heteroarencarboxamide
02/26/2004DE10225139A1 Verfahren zur Identifizierung von immunreaktiven Peptiden A method for identifying immunoreactive peptides
02/26/2004CA2496419A1 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof